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the probabilities of mother to child transmission during pregnancy and vaginal delivery or Caesarean delivery, with zidovudine treatment; and the probabilities of mother to child transmission during pregnancy and vaginal delivery or Caesarean delivery, without zidovudine treatment.
Study designs and other criteria for inclusion in the review
This was a non-systematic review of the literature. The inclusion and exclusion criteria were not given.
Sources searched to identify primary studies
Not stated.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
Three published studies were included in the review.
Methods of combining primary studies
The estimates from primary studies were combined using a narrative method.
Investigation of differences between primary studies
Results of the review
The probabilities for mother to child transmission were: 14% for breast-feeding, 18% during pregnancy and vaginal delivery without zidovudine treatment, 10% during pregnancy and Caesarean delivery without zidovudine treatment, and 8% during pregnancy and vaginal delivery with zidovudine treatment.
In the absence of preventive measures, the probability of mother to child transmission was 29%. This decreased to 23% if a Caesarean section was performed, and to 6% if all preventive measures were implemented.
Methods used to derive estimates of effectiveness
The authors made assumptions to derive other estimates of effectiveness.
Estimates of effectiveness and key assumptions
A 6% transmission rate was assumed for zidovudine treatment and a Caesarean delivery. Independent probabilities were NHS Economic Evaluation Database (NHS EED) Produced by the Centre for Reviews and Dissemination
Copyright © 2018 University of York Page: 2 / 5 assumed for breast-feeding and delivery. The uptake of zidovudine among HIV-positive pregnant women was assumed to be 75%. Forty per cent of the deliveries in HIV-positive women were assumed to be elective Caesarean sections.
Measure of benefits used in the economic analysis
The measure of benefits was the life-years gained (LYG). The benefits were measured in terms of LYG among children in whom infection with HIV was averted and in LYG because of earlier antiretroviral treatment of the mothers. Little information was given on how the LYG were calculated. It seems that they have been calculated by combining the difference in mother and child HIV cases (derived from data found in the review) with the assumed LYG per child and mother. In the base-case, a mother was assumed to gain one year and a child 70 years from detection and treatment.
Discounted (at 5%) and non-discounted LYG were estimated.
Direct costs
The cost/resource boundary of the analysis is likely to have been that of the hospital. The direct costs were for screening (test plus pre-test counselling), post-test counselling, zidovudine treatment of the mother and newborn, vaginal delivery, elective and emergency Caesarean delivery, formula feeding, and the lifetime costs of hospital and community care for a child infected with HIV. The unit costs were reported. Resource estimates were calculated using published data obtained from a London hospital between 1986 and 1996. The costs were estimated for the 1993 to 1994 financial year and indexed to 1995 to 1996 prices. The costs were discounted at 5%.
Statistical analysis of costs
No statistical analysis of the costs was carried out.
Indirect Costs
No indirect costs were included in the analysis.
Currency
UK pounds sterling ().
Sensitivity analysis
One-way sensitivity analyses were carried out. The variables investigated were the discount rate (3 or 7%), number of LYG (0 or 2), uptake of the intervention (low or high), and the lifetime cost of caring for an HIV-infected child (75 or 125% of the costs of the reference case). The interventions considered were zidovudine treatment (60, 90%), elective Caesarean section (20, 60%) and formula feeding (80, 100%).
Estimated benefits used in the economic analysis
The total number of LYG gained with universal, voluntary HIV screening of pregnant women was not reported.
Cost results
The net cost comprised the total costs of antenatal screening minus the screening benefits of averted health care for children infected with HIV.
The total cost of antenatal screening was not reported. The lifetime medical and social care cost of childhood HIV infection was 178,300.
